Merck drug extends survival in endometrial cancer trial, wins US priority review

What happened

The US health regulator accepted Merck's experimental targeted drug sac-TMT for priority review, based on a late-stage trial of 776 patients with advanced endometrial cancer. It reduced the risk of death by 32%, and a regulatory decision is expected by June 2027.

Confirmed

Global impact / market context

A priority review shortens the regulator's review time and can speed the drug to patients. For Merck, an approval would add a new cancer treatment to its product lineup, and the survival data may support its use against standard chemotherapy.

Analyst inference

The trial compared sac-TMT with chosen chemotherapy in patients whose cancer returned or progressed after earlier treatment. Stronger survival and tumor-shrinkage results may shape how doctors choose later-line treatment, while a June 2027 decision date sets the timeline investors can follow.

Analyst inference

What to watch

1. The regulator's decision is expected by June 2027, Merck said, while the company hopes for approval before that date based on talks with the FDA. Confirmed
2. Merck hopes for approval before the June 2027 PDUFA date, which is the target date for the regulator's decision, to bring the drug to patients as quickly as possible. Proposed
3. Details on severe treatment-related side effects could matter for how widely the drug is used, because safety concerns may limit use in patients with advanced endometrial cancer. Analyst inference

Evidence

• Original source link unavailable